Canadian Respiratory Journal / 2016 / Article / Tab 3

Research Article

Outcomes and Predictors of Mortality for Patients with Acute Leukemia Admitted to the Intensive Care Unit

Table 3

Characteristics of ICU survivors and nonsurvivors at ICU discharge and 1 year after ICU admission.

VariableICU discharge1-year after ICU admission
SurvivorsNonsurvivors valueSurvivorsNonsurvivors value

Leukemia type
 Acute myeloid leukemia73 (78)45 (79)0.8526 (70)91 (80)0.19
 Acute lymphoblastic leukemia21 (22)12 (21)0.8511 (30)22 (20)0.19

Chemotherapy stage
 Induction37 (39)18 (32)0.3420 (55)34 (30)0.008
 Consolidation6 (7)3 (5)12 (5)7 (6)1
 Intensification phase5 (5)0 (0)0.163 (8)2 (2)0.1
 Reinduction for relapse20 (21)9 (16)0.413 (8)26 (23)0.05
 Reinduction for nonresponse7 (8)5 (9)0.772 (5)10 (9)0.73
 Not provided chemotherapy within 40 days14 (15)19 (33)0.0085 (14)28 (24)0.15
 Unclear (no pharmacy records)0 (0)3 (5)0.050 (0)3 (3)1
 Other5 (5)0 (0)0.162 (5)3 (3)0.6

Leukemic factors
 CNS infiltration8 (9)1 (2)0.082 (5)7 (6)1
 SCT before ICU13 (14)7 (12)0.795 (14)15 (13)1
 GVHD6 (6)5 (9)0.114 (11)7 (6)1

Characteristics
 Age54 (22)57 (17)0.4253 (19)57 (20)0.12
 APACHE II25 (20–30)30 (24–39)0.00126 (22–30)28 (21–33)0.046
 SOFA9 (6–11)13 (10–15)<0.0018 (7–15)10 (8–13)<0.001
 MODS7 (5–9)8 (7–11)0.0017 (5–9)8 (6–10)0.039
 ICU length of stay (days)4 (2–7)5 (3–9)0.34 (3–8)4 (2–9)0.71

Morbidity in ICU
 Sepsis77 (82)51 (90)0.2130 (81)97 (86)0.49
 Septic shock41 (44)46 (81)<0.00113 (35)73 (65)0.002
 ARDS27 (29)29 (51)0.00411 (30)43 (38)0.36
 Stroke4 (4)4 (7)0.481 (3)7 (6)0.68

Treatments in ICU
 Invasive ventilation32 (34)50 (88)<0.00110 (27)71 (63)<0.001
  Duration of invasive ventilation (days)7 (4–20)6 (2–9)0.076 (2–10)6 (3–13)0.33
 Noninvasive ventilation (NIV)15 (16)11 (20)0.65 (14)21 (19)0.5
  Duration of NIV (days)2 (1–3)2 (2-3)0.572 (1-2)2 (1–3)0.34
 High frequency oscillation1 (1)11 (20)<0.0010 (0)12 (11)0.039
 Tracheostomy8 (9)0 (0)0.0242 (5)5 (4)1
 Renal replacement therapy (RRT)6 (6)17 (30)<0.0012 (5)20 (18)0.07
  Duration of RRT (days)6 (3–19)4 (2–6)0.393 (2–5)6 (2–9)0.55
 Insulin infusion26 (28)24 (42)0.0710 (27)40 (35)0.35

Infections identified in ICU
 Confirmed infection16 (17)22 (39)0.0035 (14)32 (28)0.07
  Bacterial13 (14)14 (25)14 (11)22 (20)1
  Viral3 (3)5 (9)0.681 (3)7 (6)1
  Fungal2 (2)5 (9)0.30 (0)6 (5)0.57

Medications administered in ICU
 Antibiotics92 (98)52 (91)0.0636 (97)107 (95)1
 Antifungals65 (69)40 (70)0.8923 (62)81 (72)0.28
 Chemotherapy28 (30)13 (23)0.3514 (38)27 (24)0.1
 Sedatives/opioids51 (54)53 (93)<0.00119 (51)84 (74)0.009
 Vasopressors43 (46)53 (93)<0.00115 (41)81 (72)0.001
 Neuromuscular blockers9 (10)17 (30)0.0014 (11)21 (19)0.27
 Steroids24 (26)23 (40)0.067 (19)39 (35)0.07
 Antipsychotics14 (15)10 (18)0.672 (5)21 (19)0.053

Data presented as (%) for categorical variables and median (IQR) for continuous variables.
APACHE = acute physiology and chronic health evaluation, CNS = central nervous system, GVHD = graft versus host disease, MODS = multiple organ dysfunction score, SCT = stem cell transplant, and SOFA = sequential organ failure assessment score.
Total number of bacterial, viral, and fungal infections in each column may be greater than the “confirmed infection” as some patients had more than 1 infection.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.